Allied Biotech Corporation (TPEX:1780)

Allied Biotech Statistics

Total Valuation

Allied Biotech has a market cap or net worth of TWD 2.51 billion. The enterprise value is 2.46 billion.

Market Cap	2.51B
Enterprise Value	2.46B

Important Dates

The next estimated earnings date is Tuesday, March 10, 2026.

Earnings Date	Mar 10, 2026
Ex-Dividend Date	Jul 17, 2025

Share Statistics

Allied Biotech has 96.24 million shares outstanding. The number of shares has increased by 0.31% in one year.

Current Share Class	96.24M
Shares Outstanding	96.24M
Shares Change (YoY)	+0.31%
Shares Change (QoQ)	+0.16%
Owned by Insiders (%)	9.11%
Owned by Institutions (%)	12.89%
Float	59.16M

Valuation Ratios

The trailing PE ratio is 26.62.

PE Ratio	26.62
Forward PE	n/a
PS Ratio	3.06
PB Ratio	2.12
P/TBV Ratio	2.12
P/FCF Ratio	18.25
P/OCF Ratio	14.89
PEG Ratio	n/a

Enterprise Valuation

The stock's EV/EBITDA ratio is 13.31, with an EV/FCF ratio of 17.91.

EV / Earnings	26.06
EV / Sales	3.00
EV / EBITDA	13.31
EV / EBIT	19.86
EV / FCF	17.91

Financial Position

The company has a current ratio of 1.61, with a Debt / Equity ratio of 0.84.

Current Ratio	1.61
Quick Ratio	1.12
Debt / Equity	0.84
Debt / EBITDA	5.38
Debt / FCF	7.24
Interest Coverage	7.14

Financial Efficiency

Return on Equity (ROE)	n/a
Return on Assets (ROA)	n/a
Return on Invested Capital (ROIC)	2.68%
Return on Capital Employed (ROCE)	10.06%
Revenue Per Employee	20.55M
Profits Per Employee	2.36M
Employee Count	40
Asset Turnover	n/a
Inventory Turnover	n/a

Taxes

In the past 12 months, Allied Biotech has paid 22.85 million in taxes.

Income Tax	22.85M
Effective Tax Rate	19.46%

Stock Price Statistics

The stock price has increased by +49.14% in the last 52 weeks. The beta is -0.12, so Allied Biotech's price volatility has been lower than the market average.

Beta (5Y)	-0.12
52-Week Price Change	+49.14%
50-Day Moving Average	22.96
200-Day Moving Average	19.12
Relative Strength Index (RSI)	67.83
Average Volume (20 Days)	211,715

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, Allied Biotech had revenue of TWD 821.81 million and earned 94.59 million in profits. Earnings per share was 0.98.

Revenue	821.81M
Gross Profit	297.87M
Operating Income	124.09M
Pretax Income	117.45M
Net Income	94.59M
EBITDA	179.57M
EBIT	124.09M
Earnings Per Share (EPS)	0.98

Balance Sheet

The company has 1.04 billion in cash and 996.19 million in debt, with a net cash position of 47.21 million or 0.49 per share.

Cash & Cash Equivalents	1.04B
Total Debt	996.19M
Net Cash	47.21M
Net Cash Per Share	0.49
Equity (Book Value)	1.19B
Book Value Per Share	12.32
Working Capital	650.33M

Cash Flow

In the last 12 months, operating cash flow was 168.68 million and capital expenditures -31.05 million, giving a free cash flow of 137.63 million.

Operating Cash Flow	168.68M
Capital Expenditures	-31.05M
Free Cash Flow	137.63M
FCF Per Share	1.43

Margins

Gross margin is 36.25%, with operating and profit margins of 15.10% and 11.51%.

Gross Margin	36.25%
Operating Margin	15.10%
Pretax Margin	14.29%
Profit Margin	11.51%
EBITDA Margin	21.85%
EBIT Margin	15.10%
FCF Margin	16.75%

Dividends & Yields

This stock pays an annual dividend of 1.00, which amounts to a dividend yield of 3.80%.

Dividend Per Share	1.00
Dividend Yield	3.80%
Dividend Growth (YoY)	17.65%
Years of Dividend Growth	1
Payout Ratio	101.51%
Buyback Yield	-0.31%
Shareholder Yield	3.48%
Earnings Yield	3.77%
FCF Yield	5.48%

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value
Lynch Upside
Graham Number
Graham Upside

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

Allied Biotech has an Altman Z-Score of 1.92 and a Piotroski F-Score of 4. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	1.92
Piotroski F-Score	4